On February 13, 2013, Tu, Wangyang; Fan, Jiang; Zhang, Haitang; Xu, Guoji; Liu, Zhiwei; Qu, Jian; Yang, Fanglong; Dong, Qing published a patent.Reference of (3aS,4S,6R,6aR)-4-(Iodomethyl)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole The title of the patent was Preparation of triazolopyrimidine derivatives as P2Y12 receptor antagonists. And the patent contained the following:
The title triazolopyrimidine derivatives I [wherein R1 = (un)substituted cycloalkyl or heteroaryl; R2 = (un)substituted alkyl; R3 = halo, (un)substituted alkyl, alkoxy, etc.; R4 = H, alkyl, etc.; or R3 and R4 together to form O or alkenyl; R5 = H, alkyl, hydroxy, etc.; or R4 and R5 together to form cycloalkyl; m = 0-2] or pharmaceutically acceptable salts thereof were prepared as P2Y12 receptor antagonists for treating myocardial infarction, embolism, cerebral ischemia, peripheral vascular disease, angina, or blood coagulation disorders. For example, II was prepared in a multi-step synthesis. In biol. test using P2Y12 receptors, II showed antagonistic activity with IC50 of 1.05 nM. The experimental process involved the reaction of (3aS,4S,6R,6aR)-4-(Iodomethyl)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole(cas: 38838-06-1).Reference of (3aS,4S,6R,6aR)-4-(Iodomethyl)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole
The Article related to preparation triazolopyrimidine p2y12 receptor antagonist human, treatment myocardial infarction embolism cerebral ischemia, peripheral vascular disease angina blood coagulation disorder and other aspects.Reference of (3aS,4S,6R,6aR)-4-(Iodomethyl)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole
Referemce:
1,3-Benzodioxole – Wikipedia,
Dioxole | C3H4O2 – PubChem